Showing 731-740 of 8816 results for "".
Galderma's Differin Goes OTC, CoolSculpting Approved for Upper Arms, ZO Skin Acquires ReFissa
https://practicaldermatology.com/series/dermwire-tv/galderma-s-differin-goes-otc-coolsculpting-approved-for-upper-arms-zo-skin-acquires-refissa/18549/Galderma's Differin Gel formulation of adapalene 0.1% is now available over the counter at major retail and drug stores in the US. ZELTIQ® Aesthetics' CoolSculpting is now FDA-cleared for fat reduction in the upper arms. ZO Skin Health has acquired the worldwide rights to ReFissa from Suneva MedicalAubio Launches, Updates from Prescriber's Choice, BioPharmX
https://practicaldermatology.com/topics/practice-management/dermwiretv-aubio-launches-updates-from-prescriber-s-choice-biopharmx/18584/In this edition of DermWireTV, Aubio launches OTC treatment for cold sores with backing from Paul Mitchell partner. Prescriber's Choice facilitates in-office prescription dispensing. BioPharmX enrolls phase 2b trial for topical minocycline and Merz acquires ONLight Sciences, maker of PFD patch for tLaser hair removal in darker skin types, challenges and technological advances for treatment
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/laser-hair-removal-in-darker-skin-types-challenges-and-technological-advances-for-treatment/18800/Andrew Alexis, MD discusses laser hair removal treatment challenges in patients with higher Fitzpatrick skin types, and how recent advances in technology have been able to address these to deliver effective treatment with minimal pain.AAD Highlights; Cyndi Lauper on Psoriasis; Qilib and More
https://practicaldermatology.com/topics/psoriasis/dermwiretv-aad-highlights-cyndi-lauper-on-psoriasis-qilib-and-more/18806/Highlights from the educational sessions at the AAD Annual Meeting; Cyndi Lauper Says there's more to Psoriasis. Galderma Launches qilib and more from the exhibit hall at AAD. Plus SkinCeuticals opens Male Aesthetics Center in DC.Allergan Board Rejects Latest Valeant Bid; Topical Jublia Approved for Onychomycosis
https://practicaldermatology.com/series/dermwire-tv/dwtv-6-12/19122/Allergan's board rejects the latest merger proposal from Valeant and the FDA approves topical Jublia for onychomycosis. LEarn about these developments and hear from the AMA's new president in this edition of DermWireTV.In-Office Photos Are an Indispensable Benefit According to Joel Schlessinger MD
https://practicaldermatology.com/topics/practice-management/in-office-photos-are-an-indispensable-benefit-according-to-joel-schlessinger-md-/19221/One way dermatologists can chart the success of their patients is by taking photos before, after and during their treatments. For over 20 years, Joel Schlessinger MD has incorporated photos of his patients into his practice. In this video, he describes the benefits of this technique. Joel SchlessVitiligo Update: Pathogenesis, Therapies, and Integrative Approaches
https://practicaldermatology.com/issues/may-june-2025/vitiligo-update-pathogenesis-therapies-and-integrative-approaches/35920/Vitiligo is a chronic autoimmune condition characterized by depigmented white patches due to melanocyte destruction, attributed to genetic factors and environmental triggers.ASDS: Dr. Farah on Hair Loss Treatment Options
https://practicaldermatology.com/conferences/asds-2024-annual-meeting/asds-dr-farah-hair-regrowth-options/29152/Ronda Farah, MD, discusses treatment options for hair loss, including platelet-rich plasma and lasers, at the 2024 American Society for Dermatologic Surgery Annual Meeting.Journal Club: New Research in Atopic Dermatitis
https://practicaldermatology.com/series/practical-dermatology-journal-club-atopic-dermatitis/journal-club-new-research-in-atopic-dermatitis/26560/Practical Dermatology Chief Medical Editor Neal Bhatia, MD, chats with dermatologist Larry Eichenfield, MD, a member of the Practical Dermatology Editorial Board, about new research in atopic dermatitis (AD), as well as practical considerations and new treatments for the condition.Phio Pharmaceuticals Takes Aim at Skin Cancer
https://practicaldermatology.com/series/c-suite-chats/phio-pharmaceuticals-takes-aim-skin-cancer/24316/In the first episode of Practical Dermatology's C-Suite Chats, Robert Bitterman, CEO of Phio Pharmaceuticals, discusses the company's patented INTASYL technology. Learn more about this platform for creating and delivering uniquely modified siRNA compounds to treat cancer.